



ASX Release

## Equity Raising to Raise up to \$1.83 million

**Melbourne, Australia; 5 August 2021:** Jayex Technology Limited (ASX: JTL) (JTL or the **Company**) is pleased to announce a proposed 1 for 3 non-renounceable entitlement offer of fully paid ordinary shares in JTL (**New Shares**) to raise up to \$1.83 million (**Entitlement Offer**) to part fund JTL's investment in Brainworks Foundry Inc ("**Brainworks**").

### Entitlement Offer Details

Term	Condition	Details
<b>Offer Price</b>	\$0.025	16.6% discount to the 15 day VWAP of JTL shares (for the period ended 4 August 2021)
<b>Share Entitlement</b>	1:3	1 New Share for every 3 Shares held on the Record Date
<b>Record Date</b>		7.00pm (AEST) on Wednesday, 11 August 2021
<b>Offer Type</b>	Non-Renounceable	Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferable. Shareholders who do not take up their Entitlements will not receive any value for those Entitlements that they do not take up.
<b>Shares to be issued under Entitlement Offer</b>	Approximately 73,484,593	Assuming Entitlement Offer is fully subscribed (or the full placement of any shortfall)
<b>Major Shareholders and Directors</b>		Covenant Holdings (WA) Pty Ltd (an entity associated with Executive Chair Michael Boyd) and each of the Directors have notified their intention to take up their full entitlement under the Entitlement Offer
<b>Ranking</b>	Equal ranking	New Shares issued under the Entitlement Offer will rank equally with existing shares
<b>Use of Funds</b>		Investment in Brainworks as announced to the market on 30 July 2021 together with working capital and as otherwise set out in the Offer Document to be sent to eligible shareholders

The Entitlement Offer, which will not be underwritten, will be offered to all shareholders with registered addresses in Australia and New Zealand, and eligible shareholders with registered addresses in Singapore, United Kingdom, Malaysia, China and Indonesia, who hold shares as at 7.00pm (AEST) on the record date (being 11 August 2021). Eligible shareholders will receive an Offer Document including a personalised entitlement and acceptance form which will provide further details of how to participate in the Entitlement Offer.

The Company has agreed to grant JP Equity Holdings Pty Ltd (**JP Equity**) first right of refusal to place any shortfall under the Entitlement Offer. JP Equity will endeavour to place any shortfall on a best endeavours basis and will be paid 6% of any funds raised from the placement of any shortfall.

**Jayex Technology Limited**  
(ACN 119 122 477)

Level 4, 100 Albert Road, South Melbourne, VIC, 3205  
T: +61 3 9692 7222 | W: <https://www.jayex.com/en-au/>



## Key Dates\*

The indicative timetable in respect of the Entitlement Offer is as follows:

Event	Date
Announcement of Entitlement Offer	Thursday, 5 August 2021
Appendix 3B and Section 708AA(2)(f) Cleansing Notice lodged with ASX	Thursday, 5 August 2021
Shares traded on an 'ex' entitlement basis	Tuesday, 10 August 2021
Record Date for eligibility to participate in the Entitlement Offer	Wednesday, 11 August 2021
Despatch of Offer Document and personalised Entitlement and acceptance forms to Eligible Shareholders	Monday, 16 August 2021
Entitlement Offer opens	Monday, 16 August 2021
Last date to extend the closing date for the Entitlement Offer	Friday, 27 August 2021
Entitlement Offer closes	Wednesday, 1 September 2021
Announcement of results of Entitlement Offer and under-subscriptions	Monday, 6 September 2021
Allotment of New Shares issued under the Entitlement Offer	Wednesday, 8 September 2021
Normal ASX trading for New Shares issued under the Entitlement Offer commence	Thursday, 9 September 2021
Dispatch of holding statements for New Shares issued under the Entitlement Offer	Friday, 10 September 2021

*\*All times are in Australian Eastern Standard Time (AEST), unless otherwise stated. This timetable is indicative only and subject to change. The Directors may vary these dates subject to the ASX Listing Rules. An extension of the Closing Date will delay the anticipated date for issue of the New Shares. The Directors also reserve the right not to proceed with the whole or part of the Entitlement Offer any time before the allotment and issue of the New Shares. In that event, the relevant application monies (without interest) will be returned in full to applicants.*

## Michael Boyd, Executive Chairman, commented:

“JTL is investing into some exciting new technology in Brainworks, and its AI driven genomic sequencing pathology business Medio Labs. Medio Labs is based in California, USA and is currently expanding its operations and moving into new premises. It is an operational business though in the early stages of its growth, the technology used in the business is unique and both increases the speed of testing as well as being extremely accurate.

“As stated in prior announcements JTL is expanding its offering to its 3,300 GP Clinics in the UK, Australia, and New Zealand, through the Jayex Connect Platform, adding new functionality in demographic data and expanding to clinical data, patient focussed data and Remote Patient Monitoring. It is a natural extension to potentially provide other technologies in the future and the investment into Brainworks gives the Company a starting position.

“Investing in Brainworks’ Medio Labs gives JTL an opportunity to be part of the future development of Genomic Pathology just as patient driven pathology testing is increasing worldwide. Covid-19 has markedly increased the demand for test at home solutions which I believe will translate to other tests that can be conveniently delivered into the home.

“This Rights Issue will in part fund the investment by JTL into Brainworks and as a Director and shareholder I will be taking up my full entitlement.”

## Further Information

If you have any queries, please call Automic Share Registry on 1300 288 664 (inside Australia) between 8.30am and 5.30pm (AEST) Monday to Friday during the offer period or, alternatively, consult your professional adviser.

**Jayex Technology Limited**  
(ACN 119 122 477)

Level 4, 100 Albert Road, South Melbourne, VIC, 3205  
T: +61 3 9692 7222 | W: <https://www.jayex.com/en-au/>



**Contacts for further information:**

Executive Chairman  
Michael Boyd  
[m.boyd@jayex.com](mailto:m.boyd@jayex.com)  
+44 (0) 731 210 6490

Media & Investor Relations  
Kate Burrell  
WE Communications  
[kburrell@we-worldwide.com](mailto:kburrell@we-worldwide.com)  
0438 680 628

---

**About Jayex Technology Limited - [www.jayex.com/en-au/](http://www.jayex.com/en-au/)**

Jayex is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Jayex Connect* – the complete cloud-based Patient Engagement Platform;
- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.

This announcement is authorised for release to the market by the Board of Directors of Jayex Technology Limited.